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1. Introduction  
Even orchiectomy/androgen depletion was proposed for treating prostate cancer in the 
middle of the last century (Attar et al., 2009a; Ross et al., 2008; Vis & Schroder, 2009), 
androgen deprivation remains to be the mainstay for advanced prostate cancer treatment. 
However, androgen depletion is usually effective for a limited duration (i.e., a median time 
of 2-3 years) and majority of the treated prostate cancer patients will develop 
unresponsiveness to the initial androgen depletion treatment and then evolves to regain the 
ability to grow despite low levels of androgens in the circulation (Chen et al., 2008; 
Mostaghel et al., 2009). These so called “castration-resistant prostate cancer (CRPC)” is 
almost incurable and becomes insignificantly responsive or resistant to most of anti-cancer, 
cytotoxic drugs except docetaxel and cabazitaxel that seem to show modest but significant 
improvement of patient survival time (de Bono et al., 2010; Petrylak et al., 2004; 
Vaishampayan et al., 2009). Evidence strongly suggests that the nuclear androgen receptor 
(AR) still plays an important role in CRPC and may be, in part, attributed to the resistance to 
cytotoxic anti-cancer drugs. Intriguingly, these CRPC patients may still respond to second 
line of AR–related treatment. Thus, it has been urgent to develop novel and more effective 
AR-related treatments for CRPC.  
Acquired resistance has been the main limitation of efficacy of cytotoxic drug chemotherapy 
and hormonal therapy for CRPC. Recently, new molecules or agents aiming at local 
angiogenesis, immunotherapy, apoptosis, chaperone proteins, the insulin-like growth factor 
(IGF) pathway, mammalian target of rapamycin (mTOR), RANK ligand, endothelin 
receptors, and the Src family kinases in CRPC have been developed for treating CRPC, some 
of which have been either approved by US Food and Drug Administration (FDA) or 
entering into different phases of clinical trial (Aggarwal & Ryan, 2011; Leo et al., 2011; 
Macfarlane & Chi, 2010; Seruga et al., 2011). This chapter will only focus on AR related 
targeting approaches for CRPC treatments.  
2. AR mediated actions in prostatic cells  
Wild type of AR is an approximately 110 kDa protein encoded by the gene on Chromosome 
Xq11-12 containing 8 exons. It is a ligand (e.g., dihydrotestosterone or DHT) dependent 
transcription factor belonging to the nuclear steroid hormone receptor superfamily (Balk & 
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Knudsen, 2008; Li & Al-Azzawi, 2009; He & Young, 2009). AR protein has three main 
functional domains consisting of an N-terminal (NTD) transactivation-1 domain (AF-1; exon 
1), a central DNA binding domain (DBD; exons 2 and 3), and a C-terminal ligand binding 
domain (LDB) with a ligand dependent activation function-2 (AF-2) (exons 4-8) and a short 
hinge region (exon 4). Normally, androgen binding to LDB in cells will induce an AR 
conformational change that facilitates its nuclear translocation and specific genomic DNA 
binding, and therefore, the consequence of the regulation of AR target gene expression.  
The functions of AR can vary depending on the cellular context of cell types. In the adult 
prostate, both stromal and secretary epithelial cells express the same AR protein. It has been 
shown that castration can induce secretary epithelial cells regress due to apoptosis in rodent 
and human prostates (Cunha & Chung, 1981; Cunha & Donjacour, 1989; Cunha & Lung, 
1978; Kurita, et al., 2001; Niu et al., 2008a; Niu & Xia, 2009; Placencio et al., 2008), but stromal 
or epithelial basal cell components remain unaffected. After replenishing with exogenous 
androgens, secretary epithelial cells will re-grow from stem cells in the basal cell layer (Heer 
et al., 2007; Niu & Xia, 2009; Vander Griend et al., 2008). It has been suggested that the AR in 
stromal cells, upon androgen stimulation, controls the out growth of the epithelial cells from 
basal cells by secreting a number of growth factors (Heer et al., 2007; Niu & Xia, 2009; 
Vander Griend et al.). The basal cells normally do not express detectable AR protein. The 
prostatic stem cells stimulated by surrounding stromal cells may out grow and differentiate 
into mature secretary epithelial cells which express AR protein. There are many known 
prostate-specific differentiation proteins, including prostatic specific antigen (PSA), human 
kallikrein-2 (hK2), prostatic alkaline phosphatase and others found to be expressed directly 
or indirectly through regulation by androgens via AR in these secretary epithelial cells (Niu 
et al., 2008b; Young et al., 2004). Thus, in the normal prostate, the role of AR in the epithelial 
cells seems to maintain a normal, terminal differentiation state of the cells. The results of 
recent studies using transgenic mouse models appear to be consistent with the above notion 
that the AR in prostatic luminar epithelial cells may function, partly, as a tumor suppressor. 
Furthermore, there are reports (Olshavsky et al., 2008; Balk & Knudsen, 2008) demonstrating 
that cyclin D3 is an intriguing cell cycle regulatory molecule that interacts with AR in 
prostatic epithelial cells and represses cell growth stimulatory activities of AR. This event 
may actually occur in in vivo, because it was found that cyclin D3 was expressed in a higher 
level in normal or benign prostate tissues than that in prostate cancer tissues. There are also 
other cell cycle regulators such as p53 and RB tumor suppressor proteins (Balk & Knudsen, 
2008; Chen et al., 2008; Goo et al., 2004; Shenk et al., 2001; Vis & Schroder, 2009) that have 
been shown to be able to interact with and regulate AR. However, their roles in regulation 
of AR functions in normal prostatic epithelial cells still require further clarification (see 
below).  
Even both prostatic epithelial and stromal cells express the same AR protein, the functions 
of AR in strmoal cells may eventually be different from that in luminar epithelial cells. In 
addition, studies have shown that the stromal AR in some conditions may act to promote 
the formation of prostate cancer (Cunha & Chung, 1981; Cunha & Donjacour, 1989; Cunha & 
Lung, 1978; Kurita, et al., 2001; Niu et al., 2009a; Niu & Xia, 2009; Placencio et al., 2008). For 
example, the mouse renal capsule tissue recombination experiments were used to 
demonstrate that only stromal AR is required for prostate epithelial development, therefore, 
the presence of epithelial AR is not required for the development of prostatic epithelia. 
Further, transgentic prostate cancer mouse models with cell-specific AR knock-out were 
used to demonstrate that the prostate stromal AR plays a more prevalent role than the 
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epithelial AR for the promotion of prostate cancer and early stages of cancer progression. 
Importantly, prostatic stroma play an important  role in inducing epithelial apoptosis 
during castration or androgen deprivation through stromal transforming growth factor-ǃ 
(TGFǃ) action (Kurita, et al., 2001; Niu & Xia, 2009; Placencio et al., 2008). Early studies 
showed that an increase of TGFǃ is associated with androgen ablation in normal/benign 
and cancer tissues (Lee et al., 1999; Kyprianou & Isaacs, 1999; Hsing et al., 1996; Brodin et al., 
1999). In more recent studies, rodent prostate models were used to show that stromal TGFǃ 
was upregulated by androgen ablation which then antagonized stromal Wnt expression and 
reduced the paracrine effect of Wnt on neighboring epithelia (Placencio et al., 2008; Li et al., 
2008). TGFǃ can also inhibit proliferation of malignant prostatic epithelial cells, however, it 
has been shown that the loss of TGFǃ receptors I and II was associated with high Gleason 
grades and with a reduce survival time in prostate cancer patients. Loss or reduction of 
expression of TGFǃ receptors I and II in prostate cancer cells has been suggested to be 
partially attributed to TGFǃ resistance in prostate cancer (Cardillo et al., 2000; Li et al., 2008).  
In transgenic TRAMP mouse models, the dominant-negative mutant TGF-beta receptor II 
expressed in mouse prostate epithelial cell seems to increase prostate tumor initiation and 
progression (Pu et al., 2009). Interestingly, the dysfunctional TGF-beta receptor II expression 
significantly enhanced AR expression at mRNA and protein levels.  However, another study 
(Turley et al., 2007) found that the decreased or lost expression of the type III TGF-beta 
receptor (TbetaRIII) could be largely accounted for TGFǃ resistance of this cancer and its 
progression because the loss or reduction of this receptor was found frequently in the cancer 
tissues. In vitro and in vivo studies showed that TbetaRIII mediates the decrease of cell 
migration and invasion as well as of tumor growth in xenografts. The results of the study 
conclude that the lost or reduced expression of this receptor correlates well with increased 
clinical stages, metastatic status, and PSA recurrence of the cancer. Further studies showed 
the reduced expression of the receptor is probably due to the combination of the loss of 
heterozygosity at the TGFBR3 genomic locus around chromosome 1p32 and epigenetic 
control of the TbetaRIII promoter.  
Increasing angiogenesis in prostate tumor areas is another important function of the AR in 
prostate stroma in order to support sufficient nutrients for cancerous prostate cells to grow.  
Reducing the expression and secretion of VEGF with subsequently decreasing micro-blood 
vessels by androgen deprivation can be attributable to another mechanism for castration-
mediated apoptosis (Cheng et al., 2004). Interestingly, it was found that, when injected into 
an AR expressing stromal environment, the androgen-independent/AR-null prostate cancer 
cells can benefit from the presence of androgens owing to its effects on angiogenesis (Cano 
et al., 2007; Halin et al., 2007).  On the other hand, castration of the rodent host can induce 
partial apoptosis of orthotopically injected AR-less prostate cancer cells due to the inhibition 
of expression of VEGF from the stroma and angiogenesis of tumor (Cano et al., 2007; 
Hammarsten et al., 2006). Castration plus administration of an inhibitor of vascular 
endothelial growth factor receptor 2 and epidermal growth factor receptor signaling, N-(4-
bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine 
(ZD6474), enhanced apoptosis of the prostate cancer tumors, suggesting a potential new 
way to treat CRPC (Cano et al., 2007; Hammarsten et al., 2006; Johansson et al., 2007). 
Moreover, studies also  showed that, by unknown mechanisms, the AR colud re-appear in 
stroma and epithelial areas of human prostate cancer tissues after castration therapy, 
therefore, this means that stromal AR could be important to the progression of CRPC and be 
a highly feasible target for CRPC treatment (Henshall et al., 2001; Ricciardelli et al., 2005; 
Wikström et al., 2007).  
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3. AR in malignant prostatic cells  
AR in malignant prostate cells shows cell proliferative stimulation and cell survival 
functions that are apparently different from that of the AR in normal epithelial cells as 
described above. In primary prostate tumor AR responds to castration or androgen 
deprivation and cause tumor regression by apoptotic cell death. AR expression may be 
reduced during the hormonal treatments. In fact during the malignant progression, both 
stromal and epithelial cells in tumor areas become resistant to hormonal deprivation 
(Henshall et al., 2001; Wikström et al., 2007). However, AR may re-appear and has been 
shown to be still expressed in the majority of CRPC as well as in a number of androgen-
independent prostate cancer cell lines. The AR in the prostate tumor cells draws a great deal 
of attention from clinicians and researchers, because it mediates not only cell growth and 
survival but also cell death in response to new hormonal treatments for CRPC cells (Attar et 
al., 2009a; Chen et al., 2008; Mostaghel et al., 2009; Ross et al., 2008; Vis & Schroder, 2009). 
Survival and proliferation of CRPC cells have been suggested as mediated by gain-of-
function changes in the AR and AR reactivation (Attar et al., 2009a; Chen et al., 2008; 
Mostaghel et al., 2009; Ross et al., 2008; Vis & Schroder, 2009). Importantly CRPC seems to 
be able to respond to second line hormonal therapy. Experimentally knocking-down of AR 
expression showing the induction of cell death in CRPC cells in cell culture and xenograft 
systems provides strong evidence that AR target therapy for CRPC is highly feasible. 
There are several mechanisms that have been widely suggested that AR still plays an 
important functioning role in promoting CRPC and can be used as therapeutic target for 
treating the cancer (Attar et al., 2009a; Chen et al., 2008; Mostaghel et al., 2009; Ross et al., 
2008; Vis & Schroder, 2009). These include (1) AR mutations and splicing variations; (2) AR 
amplification and/or overexpression; (3) de novo androgen production; (4) overexpression 
of AR co-regulators; and (5) AR activation by non-steroidal growth factors, cytokines, or 
aberrant AR phosphorylation [please see Attar et al., 2009a; Chen et al., 2008; Mostaghel et 
al., 2009; Ross et al., 2008; Vis & Schroder, 2009; Steinkamp et al., 2009 for review]. Although 
we will not further discuss all of these mechanisms, some of them with the recent new 
findings will be selected for discussion in this article in order to further enlighten the point 
of views of these mechanisms as well as new derivative concepts of the mechanisms, by 
which more efficient treatments for CRPC may be developed.  
4. AR and cell cycle in androgen dependent and CRPC cells  
As mentioned, one major role of AR in prostate cancer cells is to promote cell proliferation, 
and the AR seems to be involved in the cell cycle process (Balk & Knudsen, 2008). It has 
been suggested that androgen activated AR may direct G1-S transition in androgen 
dependent prostate cancer cells by increasing motor mediated translational activities that  
result in cyclin D1 accumulation and CDK4/cyclinD1 assembly. In this process, S-phase 
progression is further enhanced by RB phosphorylation and de-repression of cyclin A 
expression. It has been demonstrated that AR may acts as a DNA licensing factor in 
androgen responsive prostate cancer cells (D'Antonio et al., 2009). “DNA licensing” process 
occurs in a critical period of G1 phase by a temporally coordinated binding of a number of 
licensing factors including origin recognition complex (Orc1–6), cell division cycle 6 
homolog (Cdc6), chromatin licensing and DNA replication factor 1 (Cdt1), and mini 
chromosome maintenance proteins (Mcm2–7) at origins of DNA replication sites to form a 
pre-replication complex (pre-RC). Immuno-precipitation analysis showed that nuclear AR 
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was associated with the licensing proteins Orc2, Cdc-6, Cdt-1 and Mcm2. AR protein levels 
may be fluctuated along with cell cycle phases because the AR protein is degraded by 
proteasome in mitotic phase and increases in G1 phase in order to ensure next cell cycle re-
entry and re-licensing. This study (D'Antonio et al., 2009) points out the critical role of AR in 
G1 through S phase for promoting cell growth of androgen dependent prostate cancer cells 
that is different from its functions in normal prostatic cells.  
Nonetheless, a delicate study (Wang et al., 2009) reported recently the identification of a 
number of androgen regulated genes using a number of sophisticated assays including a 
global gene expression profiling and other analyses on an androgen-independent LNCaP 
sub-line to address the AR mediated proliferative function in CRPC cells.  The authors 
suggested that, instead of promoting G1/S transition by androgen activated AR in androgen 
responsive prostate cancer (ARPC) cells, ligand-free AR may play a role to drive M-phase 
transition in androgen-independent prostate cancer (AIPC) cells. This study discovered that 
many of these AR up-regulated genes are M-phase related genes. Clinical tissue samples 
from AIPC and ARPC patients were also used for gene profiling analyses which strongly 
support the conclusion obtained from the above in vitro AIPC cell model. To further prove 
the differences of AR bound genes between AIPC and ARPC cells, chromatin 
immunoprecipitation (ChIP) plus genome–wide tiled oligonucleotide microarrays (ChIP-on-
chip) was performed. The authors found that there was more AR occupancy in AR 
upregulated cell cycle and M-phase genes in AIPC cells than that in ARPC cells. The M-
phase related regulatory genes including CDC20, UBE2c CDK1 and ANAPC10 were indeed 
AR binding genes in androgen-independent (AI) LNCaP cells when a direct ChIP assays 
was performed. These M-phase genes were shown to be up-regulated by AR in the absence 
of androgens and anti-sense knock down of these genes can affect cell proliferation activity. 
This study strongly suggested that AR without exogenous androgens can regulate M phase 
gene expression for cell proliferation in AIPC/CRPC cells. M-phase regulatory genes 
become AR’s new targets, whose elevation of expression seems to be assisted with alteration 
of epigenetic marks in AIPC/CRPC cells. This also raises the possibilities that in addition to 
G1/S transition, M phase regulated by AR is also important in AIPC cells and the observed 
changes in epigenetic marks could increase the previously inaccessible AR binding sites in 
ARPC cells to become accessible by AR in AIPC/CRPC cells.  
Another possible explanation of cell cycle deregulation by AR in AIPC/CRPC cells could be 
because of alterations of the RB pathway. Although the RB tumor suppressor alterations are 
not the major events in primary prostate cancer, the alterations were observed frequently in 
prostate cancer tissues after androgen blockade treatments (Mack et al., 1989).  A study also 
showed that RB-deficient prostate cancer cells can increase susceptibility to certain 
anticancer cytotoxic agents by inducing cell death.  The authors suggested that RB depletion 
can be developed to enhance conventional cytotoxic therapeutic intervention for a subset of 
prostate cancer (Sharma et al., 2007). Recently, examination of 44 CRPC tissues with both RB 
mRNA expression levels and gene expression signature profiling of RB function loss 
indicated the frequent alterations of RB coincidence with CRPC development (Sharma et al., 
2010). Further analyzing 156 CRPC tissue samples from the 44 patients showed 115 of 156 
(73.7%) of the specimens with negative for nuclear RB immunodetection. The authors 
concluded that loss of the RB1 locus itself may be a major mechanism of RB inactivation in 
CRPC which was infrequently observed in primary disease (Sharma et al., 2010). 
Experimental evidence then demonstrated that loss of RB may enhance AR expression and 
functions even in the absence of androgens or the presence of anti-androgens via enhanced 
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E2F transcription factor 1 activity. Interestingly, RB loss/depletion can also enhance AR 
regulated M-phase genes like CDK1 described above, indicating the AR activities may be 
broadened in CRPC cells (Sharma et al., 2010; Macleod, 2010).  Furthermore, the study 
demonstrated that RB loss/depletion enhanced expression and activities of E2F-1. The 
authors (Sharma et al., 2010) concluded that the RB/E2F/AR network may provide potential 
new avenues for developing effective therapeutic intervention for CRPC as suggested 
elsewhere (Knudsen & Wang, 2010). 
Contrast to the above report (Sharma et al., 2010), an earlier study (Davis et al., 2006) 
indicated that by examining the expressions of E2F1 and AR proteins in 667 prostate tissue 
microarray cores E2F1 protein levels are low in benign and localized prostate cancer, 
moderate high in hormone native metastatic lymph nodes and significantly increased in 
CRPC metastatic tissues. However, the AR protein levels are strong in 83% benign prostate, 
100% localized prostate cancer and 80% lymph node metastasis tissues and decreased to 
40% in metastatic CRPC tissues. Additionally, forced expression of E2F1 showed inhibition 
of expression of AR mRNA and protein. The authors also used chromatin 
immunoprecipitation assays to demonstrate that the AR promoter is the target for E2F1 and 
the pocket protein family members p107 and p130 to bind and repress the expression of the 
AR gene. The reasons for the different conclusions of the two studies (i.e., Davis et al., 2006; 
Sharma et al., 2010) are not very clear. However, this study (Davis et al., 2006) did not 
examine RB status in the tissues studied.  
5. AR variants or splicing isoforms in CRPC  
Through previous structural and functional analyses, AR NTD that comprises nearly 60% of 
the coding region has been shown to exhibit constitutively active, transactivation activity 
(Dehm & Tindall, 2006; Dehm & Tindall, 2007). AF-1 embedded within NTD functions as a 
ligand-independent transcriptional activator, and there are two transactivation units TAU-1 
and TAU-5 located within the AF-1. The AF-1a (a. a.101-211) and AF-1b (a. a. 253-361) 
domains in the TAU-1 (Dehm & Tindall, 2006) and WHTLF (a. a. 435-439) motif in the TAU-
5 are the main sub-regions in mediating the ligand-independent NTD transcriptional 
activity (Dehm et al., 2007). AR protein becomes active without androgens in response to 
stimulation of several molecules such as interleukin 1 beta (IL-1ǃ), IL-6, bone-derived factors 
(Blaszczyk et al 2004; Ueda et al., 2002a; Wang & Sadar, 2006) and others via crosstalking 
mechanism in activating AR NTD. For example, TAB2, a sensor for inflammatory signals, in 
response to IL-1beta treatment was shown to interact with the AR NTD at residues 179–188 
and then recruit MEKK1, which in turn mediates dismissal of the N-CoR/HDAC co-
repressor complex from AR and allows derepression of AR target genes. Additionally, IL-
1beta induces a switch whereby anti-androgens were able to activate the AR through AR 
NTD (Ping et al., 2006). Steroid receptor coactivator-1 was also shown to respond to IL-6 
stimulation and bind the AR NTD in order to induce ligand-independent activation of the 
AR (Ueda et al 2002b). Interestingly, calpain, a calcium-dependent proteinase and highly 
expressed in prostate cancer cells (Libertini et al., 2007), was shown to be able to cleave the 
native AR into an androgen independent isoform. In vitro and in vivo analyses demonstrated 
that calpain removes the COOH-terminal ligand binding domain from an intact AR 
molecule generating a constitutively active molecule which would be highly potentially 
attributable to androgen independent growth of prostate cancer cells mediated by the AR 
isoform. However the study did not show how often this truncated AR occurs in CRPC  
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Recently three splicing variants of AR have been discovered in a castration resistant human 
CWR22Rv1 (22Rv1) prostate cancer cell line (Dehm et al 2008). One of the variants produced 
a full-length AR with a duplicated exon 3 (AR 1/2/3/CE3) and other two resulted in two 
shorter isoforms (AR 1/2/2b and AR 1/2/3/2b) devoid of ligand binding domain but with 
a novel exon 2b. All three isoforms are constitutively active transcription factors and able to 
bind an androgen responsive element as well as to promote cell growth of 22Rv1 cells in an 
androgen-independent manner. One of these variants may be detectable in other commonly 
studied cell lines. More recent study (Li et al., 2011) from the same group of the investigators 
indicated these aberrant variant expressions were derived from an intragenic rearrangement 
of an approximately 35-kb AR genomic segment containing a cluster of the above mentioned 
alternative AR exons. Genomic analysis of tissues from 14 CRPC patients revealed similar 
AR intragenic rearrangement in conjunction with AR amplification. Another study (Guo et 
al., 2009) reported the identification of over 20 splicing variants, many of which were 
derived from intronic cryptic exon splicing, in prostate cancer cells. AR3 is a major variant 
and encodes an about 80 kDa protein containing an intact NTD and a DBD domain but 
lacking a hinge region and a LBD.  Some of these variants including the AR3 can be found in 
22Rv1 prostate cancer cells. However, AR3 is different from the variants described in the 
above studies. Moreover, an AR3 specific antibody was generated, which was able to detect 
AR3 protein in benign prostatic stromal and basal epithelial cells but little expression in 
normal luminal epithelia. On the other hand, AR3 protein was expressed at higher levels in 
malignant prostatic epithelia and suggested to be a significant predictor for prostate cancer 
recurrence after prostatectomy. The study also indicated that androgen depletion forced the 
overexpression of AR3. Interestingly, AR3 protein was demonstrated largely in cytoplasm, 
however, experimental evidence showed that AR3 could act as a transcription factor via an 
ARE of AR regulated genes and promote cell proliferation in the absence of androgens. In 
addition to the variants identified in the above studies, a group of investigators (Marcias et 
al., 2010) recently also identified several novel constitutively active AR variants in this same 
CWR22R cell line, which were generated by aberrant pre-mRNA splicing or nonsense 
mutations. It will be interesting to determine if these new variants are frequently expressed 
in clinical specimens. 
Another new AR variant, ARv567es, initially identified from a series of human prostate cancer 
xenografts was also reported (Sun et al., 2010). This variant is produced by alternative 
mRNA splicing and contains an exact full amino acid sequence from exons 1-4 and a 10 
amino acid sequence from exon 8 by skipping exons 5-7. By examining 13 CRPC patients, 10 
of the patients had at least one metastasis showing positive for ARv567es. The study 
demonstrated that ARv567es protein is constitutively active and capable of forming CRPC in a 
xenograft model. Interestingly, this variant can bind wild type AR and therefore stabilize 
and increase the activities of wild type AR with or without androgens. Moreover, in a 
different report (Watson et al., 2010) a number of AR variants including the previously 
reported ones like AR3 and new ones were examined for their functions and regulation. It 
was found the expression of these variants was repressed by androgens and de-repressed by 
androgen deprivation. Some of these variants including AR3 and ARv567es as described 
above confer CRPC growth activity but other variants such as AR-V1 may show dominant 
interfering activity. Unexpected finding in this study was that the CRPC growth activity of 
the constitutively active AR variants requires the presence of the wild type AR, because an 
antiandrogen (i.e., MDV 3100; also see below) or specific siRNA for only silencing wild type 
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AR can abolish CRPC growth activity of the AR variants tested. The authors of this study 
suggested that the roles of AR variants in CRPC appear to be highly complex and the 
requirement of wild type AR for the function of AR variants indicates the need of 
developing better antiandrogens for treating CRPC.  
6. Other mechanisms for overexpression of AR in CRPC  
As already mentioned above, there are several mechanisms that have been reported to 
manifest aberrant AR functions during CRPC progression. It has been considered that AR 
over-expression and re-expression are the major mechanisms for the progression of CRPC 
after hormonal therapy (Edwards et al., 2003; Holzbeierlein et al., 2004; Linja et al., 2001). 
Although AR gene amplification is recognized as an important way for overexpression of 
AR, the amplification only occurs in 20 -30% of CRPC tumors. Therefore there are other 
mechanisms, in addition to those being already described above, as discussed below that 
could be contributed to the AR overexpression in CRPC.  
Immunohistostaining assays previously showed heterogeneity in the expression of AR 
protein increases with progression of high grade prostate cancer (Magi-Galluzzi et al., 1997; 
Pertschuk et al., 1995).  Examining the methylation status of the 5' CpG of the AR gene 
promoter showed that that approximately 20-30% of CRPC tumors losing or reducing AR 
expression, partly, by DNA hypermethylation in the AR promoter (Jarrard et al., 1998; 
Kinoshita et al., 2000; Nakayama et al.,2000; Sasaki et al., 2002; Takahashi et al., 2002). DNA 
methylation and histone modification are two major epigenetic mechanisms that can affect 
gene expression in normal and malignant cells. The above studies indicated that DNA 
methylation could be one possibility for causing heterogeneity of AR expression CRPC. 
However, it is not clear whether aberrant DNA hypomethylation in the AR gene can be a 
mechanism for overexpression and re-expression of AR. This would be a research area of 
interest to pursue. Moreover, aberrant DNA methylation in other genes may affect AR 
function.  For example, it has been demonstrated  that melanoma antigen gene protein-A11 
(MAGE-11) as a transcriptional regulator can enhance AR transcriptional activity by 
interacting through FXXLF related motifs in both NH(2)-terminal domains of AR and p300 
(Askew et al., 2010; Karpf et al., 2009). This study showed that an increased DNA 
hypomethylation in a CpG island of the MAGE-11 5’ promoter in CRPC tissues and cell 
lines may cause increased expression of MAGE-11 mRNA and protein which, in turn, 
enhances AR signal activities in CRPC. 
AR mutation may not be frequent events in CRPC, however, it becomes apparent that 
hormone therapy such as the use of anti-androgens could be a potential selection force for 
AR mutations that can affect its stability, promoter preference, or ligand specificity (Attar et 
al., 2009; Chen et al., 2008; Mostaghel et al., 2009; Ross et al., 2008; Vis & Schroder, 2009; 
Steinkamp et al., 2009). Increased stability of mutated receptor may be a factor for the 
apparent AR overexpression.  
The signal transducer and activator of transcription 5 (Stat5) has been shown to be involved 
in prostate cancer progression including development of CRPC (Dagvadorj et al., 2008; Tan 
et al., 2008; Thomas et al., 2011). Stat5 protein is capable of interacting with and increasing 
AR activity without the presence of androgens (Tan et al., 2008). It has been found that Stat5 
expression levels correlated with high grades of prostate cancer and its overexpression 
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could be used to predict early prostate cancer recurrence in patients treated with radical 
prostatectomy (Li et al., 2004, Li et al., 2005). Moreover, Stat5 immunostaining on tissue 
microarray containing 143 primary prostate cancer and 20 CRPC presented significant 
overexpression of Stat5 in short-term and long-term androgen deprivation tissues as well as 
CRPC tissues compared with untreated primary prostate cancer tissues (Thomas et al., 
2011). A Stat5 antisense oligonucleotide (ASO) was used for specific Stat5 knockdown and 
showed diminished nuclear translocation of AR and decreased AR protein stability by 
triggering its degradation via the proteasome pathway. The result of an in vivo study using 
Stat5 antisense oligonucleotide via ip injection showed that the Stat5 knockdown treatment 
significantly delayed CRPC tumor progression in a xenograft model. The study did not 
address whether Stat5 indeed increases AR expression in CRPC cells. However, it is 
conceivable that AR expression as well as functions is enhanced through its interaction with 
Stat5, thus, a potential mechanism for AR overexpression.  Stat5 should be an effective 
therapeutic target by a number of means including a specific prolactin receptor antagonist 
G129R-Prl, small-molecule inhibitors for Jak2, and oligonucleotides or RNA interference, 
etc., as suggested to remove or reduce AR from CRPC cells (Liao et al., 2010).  
It has been shown that NF- B proteins as transcription factors play critical roles in the 
development and progression of several types of human cancer (Baud & Karin, 2009; Shen & 
Tergaonkar, 2009). NF- B can be constitutively activated with a consequence of increasing 
cell proliferation and survival, reducing programmed cell death and enhancing 
angiogenesis and metastasis in many tumors. Because NF- B/p65 expression has been 
found to be higher in prostatic intraepithelial neoplasia and cancer tissues when compared 
with benign tissues, its expression levels were suggested as a predictor of PSA biochemical 
recurrence in certain prostate cancer patients (Chi et al., 2009; Jin et al., 2008; Ko et al., 2008; 
Ross et al., 2004; Sweeney et al., 2004; Zhang et al., 2009). In addition, evidence showed that 
activation of NF- B may be highly associated with the development of CRPC. NF- B 
activation can respond to several proinflammatory cytokines such as interleukin 6 and 
tumor necrosis factor alpha (TNFǂ). Intriguingly, androgen responsive and androgen 
independent PCa cells may respond to TNFǂ treatment differently. TNFǂ induces apoptosis 
in androgen responsive LNCaP cell line by activating NF- B with subsequent down-
regulation of AR mRNA and protein. It was shown that the 5'-untranslated region of the AR 
gene contains a composite response element for NF-kappaB and B-myb transcription factors 
(Ko et al., 2008). With TNFǂ treatment, NF-kappaB and B-myb were enriched in this 
composite site with a number of co-repressors including the histone deacetylase 1, 
corepressor silencing mediator of retinoid and thyroid hormone receptor and the 
corepressor-associated scaffold protein mSin3A. On the other hand, the above complex 
formation did not  appear at the composite site of the AR gene in two androgen 
independent LNCaP subline lines, C4-2 and C4-2B, which are resistant to TNFǂ treatment 
(Zhang et al., 2009). Indeed, the activated NF- B binds its responsive element in the 5’ 
promoter of the AR gene and enhances AR expression in especially CRPC cells. In fact, there 
were eight putative NF- B binding sites within the –3.6 kb 5' promoter region of the AR 
gene detected by ChIP assays (Jin et al., 2008). This seems to suggest there may be a sub set 
of CRPC progressed during androgen deprivation therapy that is associated with 
overexpression and constitutive activation of NF- B as well as AR overexpression.  NF- B 
would be an important therapeutic target for reducing AR in CRPC cells. 
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7. Overexpressed AR and AR variants in CRPC as therapeutic targets  
The failure of hormonal therapy for prostate cancer has been largely attributed to 
overexpression of AR in recurrence of the cancer (Chi et al., 2009; Joseph et al., 2009; Norris 
et al., 2009; Singh et al., 2008; Tran et al., 2009; Zhou et al., 2008). Development of more 
effective hormonal therapeutic agents targeting overexpressed AR becomes an important 
research area. Many AR antagonists previously developed are mainly ligand competitors for 
androgens and can not overcome the over-expressed AR in CRPC.  
Newer approaches have been used to develop agents that can target potential sites in the AR 
to abrogate the function of the mutated or over-expressed receptor in cancer cells (Chi et al., 
2009; Joseph et al., 2009; Norris et al., 2009; Singh et al., 2008; Tran et al., 2009; Zhou et al., 
2008; Shen & Balk, 2009). For example, it was reported that a conformation-based assay was 
used to screen a diverse small molecule library of ≈10,000 compounds in order to select 
chemicals that can inhibit the AR-gelsolin interaction (Joseph et al., 2009). Among the 87 
compounds that scored positive in the primary mammalian 2-hybrid-based assay with no 
demonstrable cell toxicity, two chemicals, D36 and D80, were selected based on their ability 
to inhibit agonist-mediated transcription of an MMTV-luciferase reporter in LNCaP cells. 
These two AR binding compounds were shown to be different from currently used AR 
antagonists such as casodex and hydroxyflutamide, because they do not compete with 
androgens for binding and do not affect AR nuclear localization. Experimental evidence 
showed they affect recruitments of co-activators and RNA pol II enzyme to AR and AR 
DNA binding ability, and subsequently loss of its ligand-induced transcription activity as 
well as inhibition of cell proliferation in AR overexpressing LNCaP cells.   
In a study shAR lentiviral vector directed AR knockout CWR22R cells which ectopically re-
express a truncated AR lacking of LBD (i.e., ARΔLBD) were used to screen the DiverSet 
Chemical Library consisting of 34,000 small molecules (Gioeli, 2010; Narizhneva et al., 2009). 
The ARΔLBD is a constitutively active AR variant capable of supporting androgen 
independent proliferation of CWR22R cells. The genome of the cells also contained 
integrated ARE linked luciferase reporter. In this cell based assay, compounds showing 
inhibited luciferase activity at least two-fold after 24 hr incubation were selected for further 
studies. Focusing on AR mediated cell proliferation, there were two types of compounds 
selected, one type caused cell death, and other reduced cell growth in cell cultures. 
Although the actual mechanisms by which these compounds act on AR, obviously not via 
AR LBD, are not known, both types of compounds can diminish in vivo prostate tumor 
growth in a xenograft model. There is no doubt that clinically relevant studies of these 
compounds will decide their potential clinical utility. 
Also, there are two new classes of small molecules isolated from sponge (Dysidea sp.) 
extract that exhibit anti-AR activity (Andersen et al., 2010; Quayle et al., 2007; Sadar, 2011; 
Sadar et al., 2008). One type of these sponge compounds are small chlorinated peptide called 
sintokamides, and the other is EPI-001 (i.e., bisphenol A diglycidic ether.HCl.H2O). The 
study showed that isolated sintokamides were able to inhbit androgen dependent AR 
activation in cells trasfected with a native androgen response element (ARE) linked 
luciferase reporter plasmid. Further studies were performed in LNCaP cells transfected with 
plasmids for the AR NTD-Gal4DBD chimera protein and the Gal4-luciferase reporter.  This 
system allows transactivation of AR NTD by forskolin without the presence of androgens 
showed that sintokamides indeed interfere with transactivation of AR NTD.  Although both 
sintokamides and EPI-001 target AR NTD activities, the latter has been studied more 
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extensively using cell based assays to measure anti AR/AR NTD activities. The studies 
provided evidence that EPI-001 may directly bind the AR NTD not the AR LBD in test tubes. 
Moreove, in cells EPI-001 seems to be able to interact with the NTD of AR and inhibit both 
the interaction of CREB binding protein (CBP) with AR AF1 and the interaction of the AR 
NTD and AR C-terminal domain. EPI-001 does not inhibit AR nucleus translocation and 
DNA binding and does not reduce AR protein levels in cells or xenograft tumors. This 
compound was shown to inhibit in vitro and/or in vivo prostate cancer cells growth 
mediated by either wild type AR or constitutively active AR variants mentioned above but 
not inhibit in vitro and/or in vivo proliferation of AR null cells like PC-3.  
The problem with currently clinically used AR antagonists such as bicalutamide (also 
known as casodex) is their low affinity to AR that can not effctively suppress AR in CRPC, 
especially at overexpressed states. This also seems to explain, in part, why the antagonists 
can become a weak agonist for CRPC that overexpresses AR. Another new approach was 
used to improve antagonist affinity to AR in order to effectively repress AR function at high 
levels (Tran et al., 2009). The investigators used a relatively high affinity and specific 
nonsteroidal AR agonist RU59063 as a starting compound for developing potential high 
affinity antagonists (Tran et al., 2009). By screening about 200 thiohydantoin derivatives of 
RU59063 for AR antagonism in human prostate cancer cells expressing elevated AR, two 
diarylthiohydantoins RD162 and MDV3100 were chosen for further biological and clinical 
studies.  It was shown that in addition to their higher affinities than bicalutamide, these two 
compounds can reduce AR nuclear translocation, DNA binding to androgen response 
elements, and recruitment of coactivators. Oral treatment of RD162 and MDV3100 
demonstrated tumor regression in mouse xenografts of human CRPC. Furthermore, 
MDV3100 was used in a Phase I/II clinical trial in 30 CRPC patients. Thirteen of 30 (43%) 
showed sustained declines (by >50%) in serum biomarker prostate-specific antigen 
concentrations. The second phase1-2 study (Scher et al., 2010) was conducted with 140 
CRPC patients in 5 US centers. The goals were to determine the safety and tolerability 
profile of MDV3100 and to establish the maximum tolerated dose. The study concluded that 
the drug had a well tolerable toxicity and was able to reduce prostate-specific antigen levels 
and circulating tumor cell counts as well as to stabilize prostate cancer metastases. It seems 
that this compound is underway for further clinical trials for advanced prostate cancer 
(Schmidt, 2011).  
Other new AR LBD antagonists have also been described. For instance, similar to the above 
studies, a new series of thiohydantoin derivatives were generated for screening AR 
antagonistic activities and led to the identification of a metabolic stable compound, 
CH5137291 (Kawata et al., 2011; Yoshino et al., 2010). This compound also showed to 
repress AR nuclear translocation and AR mediated tumor growth in xenografts. It would 
warrant further clinical studies on human patients. BMS-641988 was, an another example, 
identified as a promising AR antagonist, with more than ten times AR binding affinity 
compared to bicalutamide, in the initial preclinical studies (Attar et al., 2009b)   However, 
phase 1 clinical trial with 61 CRPC patients showed a limited anti-cancer activity with 
occurrence of seizure activity in patients, eventually leading to closure of the study 
(Rathkopf et al., 2011).  
8. Androgen synthesizing enzymes in CRPC as therapeutic targets  
Hormonal therapies can effectively reduce circulating androgens by surgical or chemical 
castration plus adrenal steroidogenic enzyme inhibitors (e.g., ketoconazole, liarozole, and 
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aminoglutethamide), however, AR can still be functionally active inside CRPC tissues.  In 
fact one of the main reasons is that androgens can be de novo synthesized in tumor cells of 
CRPC patient tissues and cell lines (Attard et al., 2009a; Cai et al., 2009; Dillard et al., 2008; 
Locke et al., 2009a; Locke et al., 2009b; Locke et al., 2008; Locke et al., 2010; Mohler, 2008; 
Mohler et al., 2011; Montgomery et al., 2008; Stanbrough et al., 2006). This relatively wide 
spread phenomenon is due to up-regulation of expression of certain 
steroidogenic/androgen synthsizing enzymes in prostate cancer cells, including FASN, 
CYP17A1, HSD3B1, HSD17B3, HSD17B6, CYP19A1, and UBT2B17. It is highly critical that 
the up-regulated steroidogenic enzymes can produce sufficient intracellular androgens to 
act as intracrine or paracrine ligands for AR in order to facilitate progression of CRPC. 
Because of the inefficiency of suppression of adrenal androgen production by using 
ketoconazole and aminoglutethamide, circulating adrenal androgens, 
dehydroepiandrosterone (DHEA) and 5’-androstenediol (ADE) could be a source for 
making high affinity androgens testosterone (T) and DHT in prostate cancer tissues by 
HSD3B, HSD17B6, AKR1C and SRD5A enzymes. Intratumor androgens can also be 
generated by the de novo or intracrine synthesis from cholesterol or other steroid precursor 
biosynthetic pathways in especially CRPC cells. It was found that in a xenograft CRPC 
progression model, the expression of proteins for cholesterol regulation including LDL-r, 
SR-B1, HMG-CoA reductase, ACAT1,2, and ABCA1) were deregulated, and influx and 
synthesis of cholesterol were increased as sources for intratumor DHT synthesis (Leon et al; 
2010). A net increase of intra-tumor androgens can be achieved by either increasing 
reductive enzymes such as HSD17B3 and HSD17B5 or decreasing those enzymes that 
catalyze the reverse oxidative reaction (e.g., HSD17B2) or both.  Also, pregnenolone and 
progesterone may be used as the initial substrates catalyzed by CYP17A in the so called 
“backdoor” pathway to produce DHEA and ADE, and DHT can be formed from the above 
products by HSD17B and SRD5A enzymes. When examining 19 local CRPC tissues, a recent 
study concluded that intratumoral steroid biosynthesis mentioned above may be less 
important than the production of intraprostatic T and DHT from adrenal androstenedione 
by overexpressed AKR1C3 and SRD5A1 in prostate cancer tissues for CRPC progression 
(Hofland et al., 2010). 
How the steroidogenic related-enzymes become deregulated remains unclear presently. It is 
possible that as discussed above, CRPC cells could adapt to have different epigenetic 
responses from that of androgen dependent prostate cancer cells. For example one could 
speculate that because chromatin structures of the steroidogenic related-enzyme genes 
become more accessible for their expression in CRPC cell, however, there is no experimental 
evidence to support it yet.  Nonetheless, a recent study showed that a proinflammatory 
cytokine, IL-6, increased expression of several steroidogenic enzymes including H SD3B2 
and AKR1C3 at mRNA and protein levels in LNCaP cells or xenografts (Chun et al., 2009). 
The up-regulation appeared to be mediated through IL-6 receptor signaling pathway, as 
shown by abolishing the up-regulation by knocking down IL-6 receptor with a specific small 
interfering RNA. The study also convincingly showed that the upregulated steroidogenic 
enzymes by IL-6 treatment indeed increased T production in LNCaP cells.  
Although an adrenal steroidogenic enzyme CYP17 inhibitor like ketoconazole has been 
widely used to repress adrenal and testicular androgen production as a second line 
hormone therapy for CRPC patients, its efficacies are not high and side-effects  including 
hepatotoxicity, gastrointestinal toxicity, and adrenal insufficiency could be severe 
(Mostaghel et al., 2009; Shah & Ryan, 2010). Corticosteroid replacement has to be used with 
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ketoconazole treatment. A recently developed, highly selective irreversible CYP17 inhibitor, 
abiraterone, presents higher potency and selectivity, and lower, manageable toxicity 
compared to ketoconazole (Attard et al., 2008; Shah & Ryan, 2010; Yap et al., 2008). Note, 
even combined with prednisone, abiraterone still showed certain degrees of adverse effects 
(e.g., fatigue, hypertension, headache, nausea, and diarrhea).. A phase I clinical trial of 21 
CRPC patients with continuous administration of abiraterone showed safety of its use and 
its antitumor activity in up to 70% of the patients (Attard et al., 2008). A phase II study by 
the same group of investigators seemed to be able to confirm the previous result (Attard et 
al., 2009b; Reid et al., 2010). Another phase II clinical trial study (Danila et al., 2010) was 
performed to determine the safety and efficacy of abiraterone when used with prednisone in 
order to reduce the secondary symptoms such as hyperaldosteronismasso.  The study had 
58 CRPC patients who had previous hormonal therapy including antiandrogens (91%), 
ketoconazole (47%) and estrogens (16%) and failed on previous docetaxel treatment.  The 
inclusion of prednisone in the abiraterone treatment seems to reduce significantly incidence 
of hypokalemia, hypertension, and fluid retention and the efficacy of abiraterone remain 
similar to previously observed. A phase III clinical trial on post-docetaxel, castration-
resistant prostate cancer patients presented a significantly increased overall survival by 
about 3.9 months compared with the placebo group (i.e., 14.8 months vs. 10.9 months). The 
clinical use of this drug seems to be much closer to an approval by U.S. FDA.  
There are also other new CYP17 inhibitors such as TAX700 and VN124-1 (Vasaitis et al., 
2008; Vasaitis et al., 2010), currently undergoing early clinical trial evaluation. VN/124-1 (3 
ǃ-hydroxy-17-(1H-benzimidazole-1-yl)androsta- 5,16-diene), also known as TOK-001, shows 
an IC50 value of 300 nM in an assay system using intact CYP17expressing Escherichia coli in 
comparison with abiraterone using the same assay system had an IC50 value of 800 nM 
(Handratta  et al., 2005; Vasaitis et al., 2008) . However, the inhibitory effect of VN/124-1 is 
not strictly specific for CYP17 because it was found this compound has multiple targets in 
androgen signaling pathways (Chan et al., 1996; Schayowitz et al., 2008; Vasaitis et al., 
2008).  For example, VN/124-1 can act as a ligand antagonist for wild type and a mutant AR 
(in LNCaP cell) for the binding of a synthetic androgen R1881 as well as in transactivation 
assay with an ARE linked luciferase reporter and has similar anti-AR potency compared to 
bicalutamide in LNCaP cells (Chan et al., 1996; Danila et al., 2010). VN/124-1 also reduces 
AR protein levels. Interestingly, VN/124-1 can inhibit proliferation of CRPC cell lines 
exhibiting overexpression levels of AR and no longer responding to antiandrogen 
bicalutamide.  In preclinical tests, VN/124-1 at a dose of 0.13 mmol/Kg  twice daily showed 
93.8% reduction of LAPC-4 tumor volume which seemed to be more effective than 
castration (Chan et al., 1996, Handratta  et al., 2005). The results of all these studies together 
seem to indicate that VN/124-1 acts as an AR antagonist as well as a CYP inhibitor. It would 
be very useful if the authors demonstrated that serum testosterone levels can be reduced by 
this compound.  
TAK-700 [(1S)-1-(6, 7-dimethoxy-2-naphthyl)-1-(1H-imidazol- 4-yl)-2-methylpropan-1-ol] 
isanon-steroidalimidazole] is a CYP17 inhibitor with IC50 = 28 nM. This is a selective 
inhibitor for CYP17 over 11 ǃ–hydroxylase (Vasaitis et al., 2010). In animal studies, TAK-700 
showed inhibitory effects on testosterone production and reduction of prostate gland and 
seminal vesicles in rats. In addition, results of testing on monkeys showed a single TAK-700 
oral administration at 1 mg/kg body weight was sufficient to decrease serum testosterone 
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levels to castration levels after 8 hours of the treatment (Matsunaga, et al., 2004). Clearly, 
clinical trials in humans will determine if this CYP inhibitor has values to treat CRPC. 
9. Conclusions  
As discussed above, surgical or medical androgen deprivation appears to be a major force to 
cause AR overexpression and gain of function with the consequence of developing CRPC. 
Intriguingly, recent studies found that androgen ablation can induce leukocytes infiltration 
into treated tumour areas. Particularly, infiltrated B cells may produce lymphotoxin which 
in turn causes IKK-ǃ activation results in production of cytokines that activate IKK-α and 
STAT3 in prostate cancer cells (Ammirante et al., 2010). The activation of STAT3 or IKK-α 
could activate AR and enhance survival of hormone-deprivation prostate cancer 
(Ammirante et al., 2010; Jin et al., 2008). Mainly due to overexpression and reactivation of 
the AR, the resistance to the hormonal deprivation treatments may be overcome by 
developing new, high affinity AR antagonists. Since recent findings indicated that CRPC 
tumor can gain the ability by up-regulating genes in androgen synthesis pathways to 
produce sufficient androgens to activate AR, searching and developing more safe and 
effective inhibitors, in addition to abiraterone, to the key enzymes in the pathways would 
also be important approaches for CRPC therapy.  
 
 
Table 1. Drug development in Targeting AR and AR  related molecules in CRPC 
Although it has been shown that the expression of the constitutively active AR variants may 
be increased by androgen deprivation and overexpressed in CPRC tissues, whether these 
AR isoforms can become prevalent in CRPC without the presence of wild type AR is 
currently unknown and should be an interesting topic for further investigation. However, if 
this will be the case, more proactive strategy for generating new types of non-ligand AR 
antagonists will be needed, because the oncogenic activities of this type of AR variants will 
no longer be inhibited by conventional antagonists. Also, AR in microenvironmental stromal 
areas that surround CRPC cells would be a useful target site. Clearly, nucleotides like 
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antisense molecules being suggested as drugs for targeting AR will have to overcome 
numerous obstacles in order to become effective and safe for CRPC treatment. Of course, 
further understanding AR activities in CRPC will help develop better ways to treat the 
advanced prostate cancer including CRPC. Finally, many laboratories have attempted to 
develop drugs targeting AR and/or AR signaling related molecules as listed in Table 1 for 
CRPC treatment, many of these potential drugs face site specificity, toxicity, efficacy, and 
delivery challenges/problems.  
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